Kathleen Schoch
@kathleenschoch
Assistant Professor @MillerLabNeuro | Founder @InPrintWUSTL | Washington University in St. Louis | University of Kentucky Physiology PhD
ID: 1030937859782529024
18-08-2018 22:01:54
116 Tweet
143 Takipçi
118 Takip Edilen
#NSFGRFP are out - congratulations to two of my favorite scientists Riley Catenacci and @Olumide_jfST!
Read our latest News & Views: Timothy Miller and colleagues discuss the most recent findings on the role of perivascular fibroblasts in the pathogenesis of amyotrophic lateral sclerosis #ALS Test Account Tim Miller nature.com/articles/s4159…
Two new tools for TREM2 research: antisense oligonucleotides and antibody single-chain variable fragments. #alzheimersdisease @WUSTL University of Oxford ow.ly/cTVo50FGCrS
Y’all. So surprised and thankful to be presented with an Outstanding Mentor Award at this summer’s WUSTL ENDURE symposium. It’s been such a pleasure working with scholars, especially Ephraim Oyetunji. ❤️
Co-authors Andrea Scharf, Amanda Daniel, PhD and Kathleen Schoch go #behindthepaper on starting InPrint: A Scientific Communication Network, a trainee-based editing service as route to improve scientific communication go.nature.com/2YtvDKf
Check it out: @WUSTL's own InPrint: A Scientific Communication Network was featured in Nature Biotechnology as an example of how to create a successful trainee-based #scicomm development program! Well done! Read it here: ow.ly/WLYp50Gtc1x
Happy to share that my last paper as postdoc in @aimee_kao lab has been published in Science Advances. Thanks to our amazing collaborators including Jennifer Yokoyama,The Cuervo Lab,Kathleen Schoch and many others. science.org/doi/10.1126/sc…
We have an #exciting announcement InPrint: A Scientific Communication Network! In the upcoming weeks, @skylervhendrix will be transitioning into the role of our #editor-in-chief! So, this is a perfect opportunity to introduce her for #MeetTheTeam Monday! Check it out! 👏 #teamwork #edit #scicomm
BREAKING: the FDA has approved a new drug called toferson for a rare form of ALS caused by mutations in the gene SOD1. #WashUMed researcher Miller Lab, MD, PhD, led the international clinical trials. ALS Center Wash U Biogen medicine.wustl.edu/news/drug-for-…